Correction (DOI:10.1016/j.jcin.2008.06.005);Outcomes and Complications With Off-Label Use of Drug-Eluting Stents. Results From the STENT (Strategic Transcatheter Evaluation of New Therapies) Group

JACC: Cardiovascular Interventions

Volumn 1, Issue 4, 2008, Pages 405-414

  Brodie, Bruce R ^a   Stuckey, Thomas ^a   Downey, William ^a   Humphrey, Angela ^b   Bradshaw, Barbara ^a   Metzger, Chris ^c   Hermiller, James ^d   Krainin, Fred ^e   Juk, Stanley ^f   Cheek, Barry ^g   Duffy, Peter ^h   Smith, Henry ⁱ   Edmunds, John ⁱ   Varanasi, Jay ⁱ   Simonton, Charles A ^j  

^a LeBauer Cardiovascular Research Foundation   (United States)

^b R Stuart Dickson Institute for Health Studies   (United States)

^c Pharmacy Services   (United States)

^d Indiana Heart Institute   (United States)

^e McLeod Health   (United States)

^f Sisters of Charity Providence Hospitals   (United States)

^g High Point Regional Health System   (United States)

^h Regional Medical Center   (United States)

ⁱ Eagle Cardiology   (United States)

^j CAROLINAS MEDICAL CENTER   (United States)

more..

Author keywords

drug eluting stents; off label indications; percutaneous coronary intervention (PCI)

Indexed keywords

ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HIRULOG; PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BYPASS SURGERY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DRUG ELUTING STENT; FEMALE; GENDER BIAS; HEART EJECTION FRACTION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; IN-STENT RESTENOSIS; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OFF LABEL DRUG USE; OUTCOMES RESEARCH; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REGISTER; REGRESSION ANALYSIS; SAPHENOUS VEIN GRAFT; ST SEGMENT ELEVATION; TREATMENT INDICATION; UNITED STATES;

EID: 49449087976     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2008.09.002     Document Type: Erratum

References (29)

1. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
2. Spaulding C., Daemen J., Boersma E., Cutlip D.E., and Serruys P. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
3. Beohar N., Davidson C.J., Kip K.E., et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 297 (2007) 1992-2000
4. Win H.K., Caldera A.E., Maresh K., et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297 (2007) 2001-2009
5. Maroquin O.C., Selzer F., Mulukutla S.R., et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med 358 (2008) 342-352
6. Shuchman M. Debating the risks of drug-eluting stents. N Engl J Med 356 (2007) 325-328
7. Simonton C.A., Brodie B.R., Cheek B., et al. Comparative clinical outcomes of paclitaxel and sirolimus-eluting stents. Results from a large prospective multicenter registry-STENT Group. J Am Coll Cardiol 50 (2007) 1214-1222
8. Cordis Corp. CYPHER sirolimus-eluting stent: essential prescribing information. http://www.cordis.com Accessed May 20, 2008
9. 2 stent system: directions for use. http://www.taxus-stent.com Accessed May 20, 2008
10. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcomes of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
11. Urban P., Gershlick A.H., Guagliumi G., et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one year follow-up of the e-Cypher Registry. Circulation 113 (2006) 1434-1441
12. Lasala JM, Cox DA, Mascioli SR, Baim DS. Expanded use of the TAXUS Express paclitaxel-eluting stent: insights on safety and long-term outcomes from the 7000 patient ARRIVE Registry Program. Paper presented at: Transcatheter Therapeutics; October, 2007; Washington, DC.
13. Lemos P.A., Serruys P.W., van Domberg R.T., et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare metal stent implantation in the "real world.". The Rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) Registry. Circulation 109 (2004) 190-195
14. Abbott J.D., Voss M.R., Nakamura M., et al. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice findings from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol 50 (2007) 2029-2036
15. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., and Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
16. James S. Swedish Coronary Angiography and Angioplasty Registry. Paper presented at: European Society of Cardiology Congress; September, 2007; Vienna, Austria.
17. Tu J.V., Bowen J., Chiu M., et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 357 (2007) 1393-1402
18. Laarman G.J., Suttorp M.J., Dirksen M.T., et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 355 (2006) 1105-1113
19. Spaulding C., Henry P., Teiger E., et al., TYPHOON Investigators. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355 (2006) 1093-1104
20. Menichelli M., Parma A., Pucci E., et al. Randomized trial of sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction (SESAMI). J Am Coll Cardiol 49 (2007) 1924-1930
21. Pasceri V., Patti G., Speciale G., Pristipino C., Richichi G., and Di Sciascio G. Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. Am Heart J 153 (2007) 749-754
22. Schofer J., Schluter M., Gershlick A.H., et al., E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind randomized controlled trial (E-SIRIUS). Lancet 362 (2003) 1093-1099
23. Ardissino D., Cavallini C., Indolfi C., et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries. A randomized trial. JAMA 292 (2004) 2727-2734
24. Schampaert E., Cohen E.A., Schluter M., et al., C-SIRUS Investigators. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRUS). J Am Coll Cardiol 43 (2004) 1110-1115
25. Kastrati A., Mehilli J., von Beckerath N., et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis. A randomized controlled trial. JAMA 293 (2005) 165-171
26. Vermeersch P., Pierfrancesco A., Verheye S., et al. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts. Results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol 50 (2007) 261-267
27. Grube E., Dawkins K.D., Guagliumi G., et al. TAXUS VI 2-year follow up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. Eur Heart J 28 (2007) 2578-2582
28. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents. An observational study of drug-eluting stents versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
29. Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168